Mutations in PURA Cause Profound Neonatal Hypotonia, Seizures, and Encephalopathy in 5q31.3 Microdeletion Syndrome

Seema R. Lalani,1,17,∗ Jing Zhang,1,17 Christian P. Schaaf,1,5,17 Chester W. Brown,1,11,17 Pilar Magoulas,1 Anne Chun-Hui Tsai,4 Areeq El-Gharbawy,5 Klaas J. Wierenga,6 Dennis Bartholomew,7 Chin-To Fong,8 Tina Barbaro-Dieber,9 Mary K. Kukolic,9 Lindsay C. Burrage,1 Elise Austin,1 Kory Keller,4 Matthew Pastore,7 Fabio Fernandez,10,11 Timothy Lotze,10,11 Angus Wifong,10,11 Gabriela Purcarin,13 Wenmiao Zhu,1 William J. Craig,1 Marianne McGuire,1 Mahim Jain,1 Erin Cooney,1 Mahshid Azamian,1 Matthew N. Bainbridge,2 Donna M. Muzny,2,14 Eric Boerwinkle,2,15 Richard E. Person,1,14 Zhiyv Niu,1,14 Christine M. Eng,1,14 James R. Lupski,1,2,11,12 Richard A. Gibbs,1,2 Arthur L. Beaudet,1 Yaping Yang,1,14 Meng C. Wang,1,16 and Fan Xia1,14,∗

5q31.3 microdeletion syndrome is characterized by neonatal hypotonia, encephalopathy with or without epilepsy, and severe developmental delay, and the minimal critical deletion interval harbors three genes. We describe 11 individuals with clinical features of 5q31.3 microdeletion syndrome and de novo mutations in PURA, encoding transcriptional activator protein Pur-a, within the critical region. These data implicate causative PURA mutations responsible for the severe neurological phenotypes observed in this syndrome.

To date, several individuals have been described as having 5q31.3 microdeletion syndrome.1–4 Shimojima et al.1 reported two individuals with profound neonatal hypotonia, feeding difficulties, an abnormal electroencephalogram (EEG), hypomyelination, and severe psychomotor delay.1 Lennox-Gastaut syndrome was diagnosed in one of these individuals, for whom seizures started at 12 months of age. Additional affected individuals were subsequently reported as presenting with marked hypotonia, respiratory insufficiency with central or obstructive sleep apnea, swallowing dysfunction, seizure-like episodes, epilepsy, and neuroimaging abnormalities.2,3 Although the deletion size varied from 2.6 to 5.0 Mb in the original report,1 subsequent individuals with smaller deletions narrowed the critical region; the shortest overlapping segment was approximately 101 kb and encompassed purine-rich element binding protein A (PURA [MIM 600473; RefSeq accession number NM_005859.4]), IgA-inducing protein (IgIP), and cysteine-rich transmembrane module containing 1 (CYSTM1).2 Although PURA has earlier been proposed as a candidate gene with mutations responsible for the neurological phenotypes in this syndrome,3 no individuals with point mutations in this gene have been described.

We identified 11 individuals with de novo heterozygous mutations in the single-exon gene PURA among 2,908 consecutive subjects referred to the Whole Genome Laboratory at Baylor College of Medicine from October 2011 to April 2014 for clinical exome sequencing.5 Approximately 70% of the individuals were pediatric subjects with a variable spectrum of neurodevelopmental disorders. Sequencing and data analysis were conducted as previously described (Yang et al.5) and targeted ~20,000 genes, including the coding and UTR exons. Average coverage for targeted regions was greater than 130×, and more than 95% of the target bases were covered by at least 20 reads. To clarify the role of PURA in 5q31.3 microdeletion syndrome, we analyzed previously unreported PURA variants found by clinical exome sequencing. Subjects were enrolled in research studies approved by the institutional review board of Baylor College of Medicine or the University of Rochester, and informed consent was obtained. Sanger sequencing confirmed the PURA mutations in all individuals and validated the absence of the relevant mutations in both parents for each of the 11 probands. For each proband, samples were obtained from the biological parents, and the transmission of multiple rare variants was verified by Sanger sequencing confirming the stated
parental relationship. Of the identified PURA mutations, four were truncating (three nonsense and one frameshift), five were missense, and two were in-frame deletions (Table 1; Figure 1A). None of these mutations were detected in 1000 Genomes (release 20110521), dbSNP134, the NHLBI Exome Sequencing Project Exome Variant Server, or the database of Atherosclerosis Risk in Communities (exome data of ~6,000 subjects). No additional contributing mutations in other genes were identified in the 11 individuals with de novo PURA variants.

The phenotype of these 11 probands (Table 1; Table S1, available online) is distinctly similar to that of 5q31 microdeletions encompassing this gene.1–5 All 11 individuals presented at birth with significant hypotonia. Respiratory insufficiency, including central and obstructive sleep apnea and recurrent pulmonary aspiration, were frequently observed. Early-onset feeding difficulties with moderate dysphagia and evidence of tracheal aspiration often necessitated nasogastric or gastric-tube feeding. Myopathic facies with an open mouth and high arched palate were common features (Figure 1B), as observed in the subjects with 5q31.3 microdeletion syndrome.1–5 Hypomyelination or myelin-maturation delay was noted on brain-imaging studies in 4/11 individuals. Myoclonic jerks in infancy were frequent, leading 6/11 children to progress to develop epilepsy. An abnormal EEG was documented in most individuals. Lennox-Gastaut syndrome was diagnosed in two individuals. Almost all of the affected children were nonverbal and nonambulatory at the time of evaluation. Prior to exome sequencing, many of these individuals had undergone extensive diagnostic evaluations, including DNA sequencing and biochemical studies for genetic conditions, such as Prader-Willi and Angelman syndromes, spinal muscular atrophy, congenital disorders of glycosylation, peroxisomal disorders, Rett syndrome, and mitochondrial disease. Our results suggest that individuals with PURA mutations share a recurring pattern of clinical features composing a recognizable phenotype and potentially establish a link between the severe neurodevelopmental profile of 5q31.3 microdeletion syndrome and transcriptional activator protein Pur-α.6

PURA encodes a highly conserved 322 amino acid multifunctional protein, Pur-α, that has important roles in DNA replication, DNA transcription, and mRNA trafficking.7 Pur-α is required for postnatal development of the murine brain and is involved in both neuronal proliferation and maturation of dendrites.8,9 It has also been shown to be important for the transport of specific mRNA molecules to sites of translation in hippocampal neurons.10 Homozygous Pura−/− mice appear normal at birth, but they develop tremors and seizures at 2 weeks and die by 4 weeks of age.8 The number of neurons is severely lower in the cerebellum, cortex, and hippocampus of these mice than in those of age-matched Pura+/− controls.8 The development of dendrites is also abnormal in the cerebellum and hippocampus of Pura−/− mice.10 Pur-α has been found to colocalize with fragile X mental retardation protein 1 homolog (FMRP) at several sites throughout dendrites in mice.10 Pur-α, the Drosophila ortholog of PURA, has been shown to interact with the RNA transcript of FMR1 at the rCGG repeats and has been implicated in neurodegeneration in the model of fragile-X-associated tremor/ataxia syndrome.11 It is postulated that this interaction might be necessary for FMR1 mRNA transport into dendrites. Similarly, Pur-α has been shown to be involved in the transport of mRNAs into the growing oocytes in Drosophila, given its expression in both follicle cells and germine cells.12 The crystal structure of the protein reveals that the functionality of Pur-α relies on the three conserved PUR motifs.13 The first and second PUR motifs function in binding of single-stranded DNA or RNA, whereas the third PUR motif is involved in the dimerization of Pur-α.12 In previous studies, targeted mutations in critical codons within the PUR motifs abolished the ability of Pur-α to bind DNA or RNA and impaired the translocation of Pur-α from follicle or nurse cells into oocytes.12,13 The mutation in codon 97 of subject 4 overlaps the Drosophila critical codon 80 mutation (causing p.Arg80Ala), previously12,13 shown to result in reduced nucleic acid binding without affecting correct folding. The missense and in-frame-deletion mutations in our study are all located at conserved sites within PUR motifs (Figure S1). Two in silico prediction tools, PolyPhen-2 and SIFT, predict that the five missense mutations have damaging effects (Table S2). Interestingly, given that this is a single-exon gene and thus not likely subject to nonsense-mediated decay, all truncating mutations found in our series will result in loss or partial loss of PUR motif(s).

To further elucidate the biological roles of PURA, we employed the model organism Caenorhabditis elegans, whose PURA ortholog is plp-1. The plp-1-null allele, ok2155, has a 1,107 bp deletion encompassing part of the promoter region and the first 255 bp of cDNA sequence involving two exons (Figure S2). We found that homozygous plp-1 (ok2155) mutants were sterile. DAPI staining showed that oocytes were absent in the plp-1 mutant (Figures 1C and 1D), suggesting a requirement of plp-1 for germline differentiation. The plp-1 mutants had defective locomotion, marked by a 3-fold reduction in speed in comparison to wild-type animals (Figure 1E; Movies S1 and S2). Compared to age-matched wild-type worms, which showed normal movement, the mutants exhibited minimal forward movement across the culture medium. The observed defects might be related to the impaired mRNA trafficking during oogenesis and neuronal activities. Together, these results suggest the essential functions of plp-1 in both somatic and germine tissues. Human PURA is expressed in the brain and ovarian tissues (Figure S3) and might have roles similar to those of plp-1.

In conclusion, we characterize the clinical features and report de novo heterozygous PURA mutations in multiple individuals with a significant neurodevelopmental phenotype recapitulating 5q31.3 microdeletion.
<table>
<thead>
<tr>
<th>Subject</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>male</td>
<td>male</td>
<td>male</td>
<td>female</td>
<td>female</td>
<td>female</td>
<td>female</td>
<td>female</td>
<td>male</td>
<td>female</td>
<td>female</td>
<td>four males, seven females</td>
</tr>
<tr>
<td>Age at evaluation</td>
<td>6 months</td>
<td>7 months</td>
<td>10 months</td>
<td>21 months</td>
<td>23 months</td>
<td>2 years</td>
<td>2 years</td>
<td>5 years</td>
<td>12 years</td>
<td>12 years</td>
<td>15 years</td>
<td>NA</td>
</tr>
<tr>
<td>Mutation</td>
<td>c.812_814delTCT (p.Phe271del)</td>
<td>c.307_308delTC (p.Ser103Hisfs*97)</td>
<td>c.289A&gt;G (p.Leu100Pro)</td>
<td>c.363C&gt;G (p.Tyr121*)</td>
<td>c.470T&gt;A (p.Met157Lys)</td>
<td>c.265G&gt;C (p.Ala89Pro)</td>
<td>c.263_265delTCG (p.Ile88_Ala89delinsThr)</td>
<td>c.596G&gt;C (p.Arg199Pro)</td>
<td>four truncating, seven nontruncating</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inheritance</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>11/11</td>
</tr>
<tr>
<td>Hydrotonia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>11/11</td>
</tr>
<tr>
<td>Feeding difficulties</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>11/11</td>
</tr>
<tr>
<td>Respiratory difficulties</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>10/10</td>
</tr>
<tr>
<td>Seizures onset</td>
<td>3 weeks</td>
<td>neonatal</td>
<td>ND</td>
<td>5 months</td>
<td>3 months</td>
<td>neonatal</td>
<td>3 years</td>
<td>4 years</td>
<td>ND</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizure type</td>
<td>myoclonic, secondary generalized tonic</td>
<td>myoclonic jerks</td>
<td>myoclonic jerks, exaggerated startle</td>
<td>generalized tonic clonic</td>
<td>myoclonic jerks</td>
<td>myoclonic jerks</td>
<td>myoclonic, generalized tonic and atonic</td>
<td>Lennox-Gastault syndrome</td>
<td>Lennox-Gastault syndrome</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal EEG</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>NA</td>
</tr>
<tr>
<td>Psychomotor delay</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>11/11</td>
</tr>
<tr>
<td>Nonverbal</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>8/8</td>
</tr>
<tr>
<td>Ambulatory</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>1/8</td>
</tr>
<tr>
<td>Craniofacial features</td>
<td>nondysmorphic high arched palate, upturned nose, simple lobulation of ears, intermittent exotropia</td>
<td>nondysmorphic myopathic facies, strabismus</td>
<td>myopathic facies, tented upper lip, nystagmus</td>
<td>myopathic facies, left-eye esotropia</td>
<td>myopathic facies, nystagmus, strabismus</td>
<td>myopathic facies, high arched palate, nystagmus</td>
<td>myopathic facies, high arched palate, wide nasal bridge and tip, hypoplastic alae nasi, strabismus, myopia</td>
<td>nondysmorphic, palpebral fissures long, nystagmus</td>
<td>nondysmorphic, palpebral fissures long, nystagmus</td>
<td>NA</td>
<td>1/8</td>
<td></td>
</tr>
</tbody>
</table>

See Table S1 for additional details of clinical presentations. Abbreviations are as follows: EEG, electroencephalogram; NA, not applicable; and ND, not determined because of availability or applicability.
syndrome. Considering all 2,117 pediatric subjects who had a neurodevelopmental disorder and were studied by clinical exome sequencing in our laboratory, the 11 heterozygous mutations in PURA account for ~0.52% and are exceeded only by those in well-established genes ARID1B (MIM 614556; 21 subjects [0.99%]) and ANKRDI1 (MIM 611192; 13 subjects [0.61%]). Notably, our observed frequency of pathogenic events in ARID1B is consistent with the 0.9% rate previously reported by Hoyer et al.\textsuperscript{14}

PURA mutations should be considered in the evaluation of infants with profound neonatal hypotonia, myoclonic jerks, respiratory insufficiency, and an abnormal EEG. Although further investigations are essential for understanding the effects of PURA haploinsufficiency on encephalopathy with or without epilepsy, this study is an important step toward the clinical and molecular characterization of this disease, which is typically associated with a significant neurological outcome.

Supplemental Data
Supplemental Data include three figures, two tables, and two movies and can be found with this article online at http://dx.doi.org/10.1016/j.ajhg.2014.09.014.

Acknowledgments
We are grateful to the families for participating in the study. This study was supported in part by the Doris Duke Foundation and Gillson-Longenbaugh Foundation to S.R.L., by the Joan and Stanford Alexander Family Foundation to C.P.S., and by NIH grants to R.A.G. (R01AG045183), L.C.B. and M.J. (T32GM07526). The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from genetic testing offered in the Whole Genome Laboratory and Medical Genetics Laboratories. J.R.L. is a paid consultant for Athena Diagnostics, holds stock ownership in 23andMe and Ion Torrent Systems, and is a coinventor on United States and European patents related to molecular diagnostics. M.N.B. is a founder of Codified Genomics.
Web Resources

The URLs for data presented herein are as follows:

1000 Genomes, http://www.1000genomes.org/
Atherosclerosis Risk in Communities Study, http://www2.cscc.unc.edu/aric/
Baylor College of Medicine Whole Genome Laboratory, https://www.bcm.edu/research/medical-genetics-labs/wholegenomelab
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org/
PolyPhen2, http://genetics.bwh.harvard.edu/pph2/
SIFT, http://sift.jcvi.org/

Accession Numbers

The ClinVar accession numbers for the DNA variant data reported in this paper are SCV000189113, SCV000189114, SCV000189115, SCV000189116, SCV000189117, SCV000189118, SCV000189119, SCV000189120, SCV000189121, SCV000189122, and SCV000189123.

References